STOK has 36-month beta value of 0.95. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for STOK is 43.10M, and currently, short sellers hold a 16.84% ratio of that float. The average trading volume of STOK on January 07, 2025 was 566.58K shares.
STOK) stock’s latest price update
Stoke Therapeutics Inc (NASDAQ: STOK) has experienced a decline in its stock price by -15.43 compared to its previous closing price of 11.02. However, the company has seen a fall of -13.70% in its stock price over the last five trading days. businesswire.com reported 2025-01-07 that BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced alignment with global regulatory agencies on the design of the Company’s Phase 3 EMPEROR study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome. Following successful interactions with the FDA, EMA and PMDA, the Company has finalized.
STOK’s Market Performance
STOK’s stock has fallen by -13.70% in the past week, with a monthly drop of -25.86% and a quarterly drop of -18.25%. The volatility ratio for the week is 5.08% while the volatility levels for the last 30 days are 6.35% for Stoke Therapeutics Inc The simple moving average for the past 20 days is -19.99% for STOK’s stock, with a -29.32% simple moving average for the past 200 days.
Analysts’ Opinion of STOK
Many brokerage firms have already submitted their reports for STOK stocks, with Chardan Capital Markets repeating the rating for STOK by listing it as a “Buy.” The predicted price for STOK in the upcoming period, according to Chardan Capital Markets is $24 based on the research report published on December 20, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see STOK reach a price target of $18. The rating they have provided for STOK stocks is “Outperform” according to the report published on October 14th, 2024.
STOK Trading at -23.40% from the 50-Day Moving Average
After a stumble in the market that brought STOK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.99% of loss for the given period.
Volatility was left at 6.35%, however, over the last 30 days, the volatility rate increased by 5.08%, as shares sank -29.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.32% lower at present.
During the last 5 trading sessions, STOK fell by -13.33%, which changed the moving average for the period of 200-days by +56.26% in comparison to the 20-day moving average, which settled at $11.65. In addition, Stoke Therapeutics Inc saw -15.50% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at STOK starting from Skorpios Trust, who sale 2,000,000 shares at the price of $11.50 back on Dec 23 ’24. After this action, Skorpios Trust now owns 6,906,181 shares of Stoke Therapeutics Inc, valued at $23,000,000 using the latest closing price.
Blue Horizon Enterprise Ltd, the Affiliate of Stoke Therapeutics Inc, proposed sale 2,000,000 shares at $11.59 during a trade that took place back on Dec 23 ’24, which means that Blue Horizon Enterprise Ltd is holding shares at $23,180,000 based on the most recent closing price.
Stock Fundamentals for STOK
Current profitability levels for the company are sitting at:
- -7.01 for the present operating margin
- 0.73 for the gross margin
The net margin for Stoke Therapeutics Inc stands at -6.3. The total capital return value is set at -0.48. Equity return is now at value -52.06, with -39.56 for asset returns.
Currently, EBITDA for the company is -112.3 million with net debt to EBITDA at 1.28. When we switch over and look at the enterprise to sales, we see a ratio of 20.44. The receivables turnover for the company is 24.23for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.09.
Conclusion
To put it simply, Stoke Therapeutics Inc (STOK) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
